The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

June 12, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with Sjögren’s syndrome may develop salivary gland mucosa-associated lymphoid tissue non-Hodgkin’s lymphoma (MALT-NHL), a condition that can be lethal. Chiara Baldini, MD, a rheumatologist at the University of Pisa in Italy, and colleagues identified the P2X7 receptor (P2X7R)-inflammasome axis as a potential novel pathway in both Sjögren’s syndrome exocrinopathy and lymphomagenesis. Their research, published online May 15 in the Journal of Internal Medicine, supports the hypothesis that P2X7R mediates the increased production of IL-18 that is, in turn, important for the pathogenesis of lymphoproliferative malignancies.1

You Might Also Like
  • Innate Immune Response Enters Center Stage for Inflammatory Eye Disease
  • Research Identifies Two New Cell Types in Sjögren’s Syndrome
  • Sialendoscopy Enhances Salivary Flow in Sjogren’s Syndrome
Also By This Author
  • Chronic Fatigue Syndrome: Are There Different Phenotypes?

“In this prospective observational study, through the investigation of the expression of the axis P2X7R-inflammasome in minor salivary gland biopsies of patients with [Sjögren’s syndrome] and different severity in the lymphoid organization, we propose for the first time a putative biomarker likely able to predict the development of this severe complication, suggesting a novel, highly relevant clinical application of the bench determination of this pro-inflammatory platform,” write the authors in their discussion. “We initially started to confirm, in a larger group of patients our previous observations that the P2X7R-inflammasome complex was significantly more expressed in [Sjögren’s syndrome] patients with respect to controls, and even more in those [Sjögren’s syndrome] patients presenting a positivity for anti-Ro/SSA and higher focus score in the salivary gland biopsies. This observation supports the amount of data in favor of the potential involvement of innate immune response in the pathogenesis of [Sjögren’s syndrome], also suggesting that this inflammasome might account for the severity and the complexity of the infiltrate composition.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although previous researchers have explored whether polymorphisms in the gene that encodes P2X7R may serve as biomarkers for lymphoproliferative diseases, the results have been contradictory. Similarly, the investigators note that they did not find a difference between the patient populations in the expression of P2X7R in peripheral monocytes. However, they did find increased expression of the P2X7R-inflammasome axis in glandular biopsies that were taken at the diagnosis of Sjögren’s syndrome, years before the development of MALT-NHL. These patients with Sjögren’s syndrome who went on to develop MALT-NHL not only had increased expression of the P2X7R-inflammasome axis, but also had glandular expression of IL-18 that was approximately three-fold higher than controls or patients with Sjögren’s syndrome who did not develop MALT-NHL.

“Our data reinforce the potential role of innate autoimmunity in [Sjögren’s syndrome] glandular inflammation and damage, focusing the attention on the axis P2X7R-inflammasome as a novel potential pathway involved in both [Sjögren’s syndrome] exocrinopathy and lymphomagenesis,” conclude the authors in their paper. “Pending the confirmation of this preliminary observation in larger cohorts of patients, P2X7R-inflammasome axis could represent an interesting biomarker for lymphomagenesis in [Sjögren’s syndrome], opening novel opportunities for the early diagnosis of lymphoproliferative complications and for the development of potential targeted therapies for the disease.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Cancer, non-Hodgkin’s lymphoma, P2X7 receptor inflammasome, Sjögren's syndrome

You Might Also Like:
  • Innate Immune Response Enters Center Stage for Inflammatory Eye Disease
  • Research Identifies Two New Cell Types in Sjögren’s Syndrome
  • Sialendoscopy Enhances Salivary Flow in Sjogren’s Syndrome
  • Early Onset of Primary Sjögren’s Syndrome May Carry a Worse Prognosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.